# RAS and Coagulopathy in COVID19

> **NCT04419610** · EARLY_PHASE1 · COMPLETED · sponsor: **Imperial College London** · enrollment: 28 (actual)

## Conditions studied

- COVID

## Interventions

- **BIOLOGICAL:** TRV027
- **OTHER:** sodium chloride 0.9%

## Key facts

- **NCT ID:** NCT04419610
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-09
- **Primary completion:** 2021-05-12
- **Final completion:** 2021-05-12
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04419610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04419610, "RAS and Coagulopathy in COVID19". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04419610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*